Scientists Develop Gene-Activating Technique

The study findings are significant because they demonstrate the most effective and consistent method developed so far for prompting genes to make the proteins necessary for gene expression, said senior author Dr. David Corey, a professor of pharmacology.

Scientists Develop Gene-Activating Technique - Forbes.com

Rumors Fly About Bristol, Lifting Stock

Shares of both Bristol-Myers Squibb and its supposed suitor, Sanofi-Aventis, traded heavily yesterday on speculation that the companies might merge to form one of the world’s largest drug companies.

Rumors Fly About Bristol, Lifting Stock - New York Times

In need of cash, Dems see billions in biotech

In need of cash, Dems see billions in biotech: "Senior Democratic lawmakers are close to introducing legislation to create a pathway for the approval of generic biological drugs in the hopes that the cheaper medicines will create billions of dollars in budget savings, which could be used to offset some of the cost of expanding federal health programs"

Virulent TB in South Africa May Imperil Millions - New York Times

Virulent TB in South Africa May Imperil Millions - New York Times: "The form of TB, known as XDR for extensively drug-resistant, cannot be effectively treated with most first- and second-line tuberculosis drugs, and some doctors consider it incurable. Since it was first detected last year in KwaZulu-Natal Province, bordering the Indian Ocean, additional cases have been found at 39 hospitals in South Africa’s other eight provinces. In interviews on Friday, several epidemiologists and TB experts said the disease had probably moved into Lesotho, Swaziland and Mozambique — countries that share borders and migrant work forces with South Africa — and perhaps to Zimbabwe, which sends hundreds of thousands of destitute refugees to and from South Africa each.

MDS Buying Molecular Devices for $615M

And now for the most expected sale in life sciences...as predicted by many over many years, only question was who.

Drug developer MDS Inc. said Monday it is buying bioanalytical measurement systems maker Molecular Devices Corp. for $615 million in cash. Under terms of the deal, MDS will pay $35.50 per share for all outstanding shares of Molecular Devices. The offer represents a 48.7 percent premium over Molecular Devices' closing price of $23.88 on Friday. The total price includes $585 million to buy outstanding shares plus $30 million for outstanding stock options

MDS Buying Molecular Devices for $615M

Potential Method of Blocking Cancer Cell Growth Identified - Yahoo! News

Potential Method of Blocking Cancer Cell Growth Identified - Yahoo! News: "This method of preventing the growth of cancer cells may provide new targets for new cancer drugs, Wagner said. 'These drugs would work on the principle of inhibiting protein-protein interactions,' he said."

Blog Archive